| 29.97 0.37 (1.25%) | 10-24 15:04 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 38.78 | 1-year : | 45.3 |
| Resists | First : | 33.2 | Second : | 38.78 |
| Pivot price | 26.88 |
|||
| Supports | First : | 28.45 | Second : | 25.52 |
| MAs | MA(5) : | 27.61 |
MA(20) : | 26.97 |
| MA(100) : | 32.88  |
MA(250) : | 33.61 |
|
| MACD | MACD : | -0.9 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 75.1 |
D(3) : | 52.4 |
| RSI | RSI(14): 60.3 |
|||
| 52-week | High : | 41.61 | Low : | 25.52 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HRMY ] has closed Bollinger Bands are 4.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.9 - 30.01 | 30.01 - 30.1 |
| Low: | 26.77 - 26.9 | 26.9 - 27.01 |
| Close: | 29.39 - 29.57 | 29.57 - 29.75 |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Fri, 24 Oct 2025
H.C. Wainwright reaffirms Harmony Biosciences stock rating on strong WAKIX sales - Investing.com
Fri, 24 Oct 2025
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Fri, 24 Oct 2025
Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last? - Nasdaq
Thu, 23 Oct 2025
Harmony Biosciences (HRMY): Revisiting Valuation Following Raised 2025 Revenue Guidance and Strong WAKIX Growth - simplywall.st
Thu, 23 Oct 2025
Harmony Biosciences Rises 10.6% On Strong Q3 WAKIX Results And Upgraded Guidance - Nasdaq
Thu, 23 Oct 2025
Harmony Biosciences (HRMY) Boosts Revenue Forecast for 2025 - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 11 (%) |
| Held by Institutions | 95.2 (%) |
| Shares Short | 3,230 (K) |
| Shares Short P.Month | 4,330 (K) |
| EPS | 3.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.43 |
| Profit Margin | 23.4 % |
| Operating Margin | 24 % |
| Return on Assets (ttm) | 14.1 % |
| Return on Equity (ttm) | 27.5 % |
| Qtrly Rev. Growth | 16 % |
| Gross Profit (p.s.) | 10.51 |
| Sales Per Share | 13.42 |
| EBITDA (p.s.) | 4.27 |
| Qtrly Earnings Growth | 240 % |
| Operating Cash Flow | 259 (M) |
| Levered Free Cash Flow | 198 (M) |
| PE Ratio | 9.68 |
| PEG Ratio | 0 |
| Price to Book value | 2.23 |
| Price to Sales | 2.23 |
| Price to Cash Flow | 6.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|